OCS
Oculis Holding AG NASDAQ Listed May 18, 2021$12.00
+2.21%
vs $11.74
Mkt Cap $628.3M
52w Low $10.71
5.9% of range
52w High $32.65
50d MA $22.19
200d MA $22.68
P/E (TTM)
—
EV/EBITDA
—
P/B
3.2x
Debt/Equity
0.0x
ROE
—
P/FCF
-10.1x
RSI (14)
63.60
ATR (14)
$0.66
Beta
0.21
50d MA
$22.19
200d MA
$22.68
Avg Volume
1.0M
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
Bahnhofstrasse 7 · Zug, V8 6300 · CH
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | TNS | -0.48 | -0.51 | -6.7% | 27.57 | +0.0% | +0.5% | +0.1% | -2.8% | +1.7% | +4.5% | — |
| Nov 10, 2025 | TNS | -0.50 | -0.40 | +20.0% | 19.42 | +0.4% | -0.1% | -2.6% | +2.1% | +1.6% | -2.3% | — |
| Aug 21, 2025 | TNS | -0.53 | -0.59 | -11.3% | 17.80 | +0.4% | +0.3% | -0.3% | -1.5% | -1.1% | -5.7% | — |
| May 8, 2025 | TNS | -0.51 | -0.77 | -51.0% | 18.70 | +0.8% | -0.6% | -5.3% | +0.9% | -2.7% | +5.9% | — |
| Mar 11, 2025 | TNS | -0.48 | -0.76 | -58.3% | 18.40 | -4.9% | +2.4% | -0.7% | +0.4% | +0.3% | +0.7% | — |
| Nov 7, 2024 | TNS | -0.52 | -0.55 | -5.8% | 16.80 | +0.0% | -3.1% | -1.8% | -6.3% | -1.8% | -0.1% | — |
| Aug 27, 2024 | TNS | -0.43 | -0.56 | -30.2% | 11.91 | +0.8% | +1.5% | -0.3% | -0.4% | +0.0% | -0.1% | — |
| May 8, 2024 | TNS | -0.41 | -0.44 | -7.3% | 12.37 | -1.5% | -3.2% | +0.8% | +0.0% | +0.7% | -1.2% | — |
| Mar 18, 2024 | TNS | -0.42 | -0.38 | +9.5% | 11.85 | -1.9% | -0.1% | +0.3% | -2.1% | +0.9% | -0.3% | — |
| Nov 15, 2023 | TNS | -0.36 | -0.38 | -5.6% | 9.81 | +0.9% | +0.0% | -1.0% | -1.0% | +0.9% | +1.5% | — |
| Aug 29, 2023 | TNS | -0.33 | -0.38 | -15.2% | 13.37 | +0.2% | -0.5% | -1.5% | -2.5% | -1.3% | +2.4% | — |
| Mar 31, 2023 | TNS | — | -1.51 | — | 7.43 | +0.8% | +5.0% | +3.8% | -1.0% | -0.1% | +1.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 21 | Guggenheim | Initiates | Buy | $75 | $27.91 | $29.00 | +3.9% | +11.1% | -4.9% | +1.5% | -1.1% | +0.1% |
| Apr 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.46 | $27.99 | +1.9% | +4.2% | -4.3% | +1.7% | -3.9% | -1.2% |
| Mar 5 | Stifel | Maintains | Buy → Buy | — | $27.72 | $28.33 | +2.2% | +0.1% | -2.8% | +1.7% | +4.5% | -4.8% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.57 | $27.57 | +0.0% | +0.5% | +0.1% | -2.8% | +1.7% | +4.5% |
| Mar 4 | Needham | Maintains | Buy → Buy | — | $27.57 | $27.57 | +0.0% | +0.5% | +0.1% | -2.8% | +1.7% | +4.5% |
| Dec 19 | Stifel | Maintains | Buy → Buy | — | $19.48 | $20.75 | +6.5% | +9.1% | -4.2% | +0.6% | +1.0% | -0.9% |
| Nov 13 | BofA Securities | Maintains | Buy → Buy | — | $18.90 | $18.90 | +0.0% | +2.1% | +1.6% | -2.3% | +0.7% | -0.1% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.42 | $19.50 | +0.4% | -0.1% | -2.6% | +2.1% | +1.6% | -2.3% |
| Nov 11 | Chardan Capital | Maintains | Buy → Buy | — | $19.42 | $19.50 | +0.4% | -0.1% | -2.6% | +2.1% | +1.6% | -2.3% |
| Nov 11 | Needham | Maintains | Buy → Buy | — | $19.42 | $19.50 | +0.4% | -0.1% | -2.6% | +2.1% | +1.6% | -2.3% |
| Oct 8 | Chardan Capital | Maintains | Buy → Buy | — | $19.06 | $19.50 | +2.3% | +4.2% | +6.3% | -0.2% | -0.4% | +2.6% |
| Oct 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.56 | $19.25 | +3.7% | +2.7% | +4.2% | +6.3% | -0.2% | -0.4% |
| Aug 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.80 | $17.88 | +0.4% | +0.3% | -0.3% | -1.5% | -1.1% | -5.7% |
| May 9 | Chardan Capital | Maintains | Buy → Buy | — | $18.70 | $18.85 | +0.8% | -0.6% | -5.3% | +0.9% | -2.7% | +5.9% |
| Apr 17 | Chardan Capital | Maintains | Buy → Buy | — | $18.02 | $18.55 | +2.9% | +1.4% | -0.8% | -1.9% | +0.6% | +0.9% |
| Apr 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.02 | $18.55 | +2.9% | +1.4% | -0.8% | -1.9% | +0.6% | +0.9% |
| Mar 13 | Chardan Capital | Maintains | Buy → Buy | — | $18.84 | $18.80 | -0.2% | -0.7% | +0.4% | +0.3% | +0.7% | -1.2% |
| Mar 13 | Baird | Maintains | Outperform → Outperform | — | $18.84 | $18.80 | -0.2% | -0.7% | +0.4% | +0.3% | +0.7% | -1.2% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.84 | $18.80 | -0.2% | -0.7% | +0.4% | +0.3% | +0.7% | -1.2% |
| Jan 7 | Chardan Capital | Maintains | Buy → Buy | — | $17.65 | $18.00 | +2.0% | +3.2% | +2.6% | +13.1% | +5.8% | +0.3% |
| Jan 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.56 | $18.10 | +3.1% | +0.5% | +3.2% | +2.6% | +13.1% | +5.8% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.28 | $16.54 | +1.6% | -1.8% | -6.3% | -1.8% | -0.1% | -3.9% |
| Oct 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.81 | $16.49 | +4.3% | +2.8% | -1.9% | -0.9% | +7.9% | -0.5% |
| Aug 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.91 | $12.00 | +0.8% | +1.5% | -0.3% | -0.4% | +0.0% | -0.1% |
| Jun 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.00 | $11.95 | -0.4% | -0.7% | -0.6% | -0.4% | +0.0% | -0.4% |
| Jun 11 | BofA Securities | Maintains | Buy → Buy | — | $12.00 | $11.95 | -0.4% | -0.7% | -0.6% | -0.4% | +0.0% | -0.4% |
| Jun 11 | Chardan Capital | Maintains | Buy → Buy | — | $12.00 | $11.95 | -0.4% | -0.7% | -0.6% | -0.4% | +0.0% | -0.4% |
| Jun 11 | Baird | Maintains | Outperform → Outperform | — | $12.00 | $11.95 | -0.4% | -0.7% | -0.6% | -0.4% | +0.0% | -0.4% |
| May 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.93 | $11.81 | -1.0% | -2.0% | +0.6% | -0.5% | +1.3% | +0.8% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.07 | $12.10 | +0.2% | +0.0% | +0.7% | -1.2% | -0.3% | +0.1% |
| Apr 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.97 | $12.01 | +0.3% | +0.1% | -0.3% | +0.6% | +5.9% | +2.7% |
| Mar 19 | Baird | Maintains | Outperform → Outperform | — | $11.85 | $11.62 | -1.9% | -0.1% | +0.3% | -2.1% | +0.9% | -0.3% |
| Mar 19 | Chardan Capital | Maintains | Buy → Buy | — | $11.85 | $11.62 | -1.9% | -0.1% | +0.3% | -2.1% | +0.9% | -0.3% |
| Mar 6 | Wedbush | Maintains | Outperform → Outperform | — | $12.08 | $12.00 | -0.7% | -1.9% | -0.6% | -1.4% | +0.2% | +1.3% |
| Feb 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.19 | $12.15 | -0.3% | -2.4% | +0.8% | +1.2% | -0.5% | -1.9% |
No insider trades available.
No recent filings available.
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 3
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Small Cap Core Fund | 6,295 | $167K | Mar 2026 |
| 2 | Virtus AlphaSimplex Global Alternatives Fund | 872 | $23K | Mar 2026 |
| 3 | First Trust IPOX Europe Equity Opportunities ETF | 110 | $3K | Mar 2026 |
Valuation
Market Cap
$628.3M
Enterprise Value
$415.0M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.60x
P/B
3.20x
P/S
1246.62x
P/FCF
-10.05x
EV/EBITDA
—
Shares Out
52.4M
Financials (TTM)
Revenue
$504K
Net Income
-$95.1M
EBITDA
-$94.1M
Free Cash Flow
-$62.5M
Op Cash Flow
-$62.2M
EPS Basic
$-1.81
EPS Diluted
$-1.73
EPS Forward
$-1.78
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$236.2M
Total Liab.
$39.9M
Total Equity
$196.3M
Cash
$213.3M
LT Debt
$0
Book Value/Sh
$3.75
Debt/Equity
0.01x
Current Ratio
5.96
Quick Ratio
5.96
Returns & Growth
ROE
—
ROA
—
ROIC
-39.6%
Rev Growth YoY
-100.0%
EPS Growth YoY
+14.6%
Price Returns
2W
-24.9%
1M
-17.4%
3M
-22.8%
6M
+19.5%
12M
+16.7%
Technicals
52W High
$32.65
52W Low
$10.71
50d MA
$22.19
200d MA
$22.68
RSI (14)
63.60
ATR (14)
$0.66
Beta
0.21
Avg Volume
1.0M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$50.00
High
$50.00
Low
$50.00
Median
$50.00
Data updated apr 26, 2026 4:53pm
· Source: financialmodelingprep.com